Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 151-165 , March 2008

Preconditioning, anesthetics, and perioperative medication

  • Yon Hee Shim, MD (Research Fellow)
    • ,
  • Judy R. Kersten, MD (Professor and Vice-Chair of Anesthesiology, and Professor of Pharmacology and Toxicology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, USA. Tel.: +1 414 456 5733; Fax: +1 414 456 6507.

References 

  1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–1136
  2. Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium. Basic Research in Cardiology. 1997;92:159–167
  3. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. American Journal of Physiology. Heart and Circulatory Physiology. 2003;285:H579–H588
  4. Bland JH, Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology. 1976;45:287–293
  5. Davis RF, DeBoer LW, Rude RE, et al. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion. Anesthesiology. 1983;59:402–411
  6. Warltier DC, al-Wathiqui MH, Kampine JP, Schmeling WT. Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology. 1988;69:552–565
  7. Kersten JR, Schmeling TJ, Pagel PS, et al. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology. 1997;87:361–370
  8. Kevin LG, Novalija E, Riess ML, et al. Sevoflurane exposure generates superoxide but leads to decreased superoxide during ischemia and reperfusion in isolated hearts. Anesthesia and Analgesia. 2003;96:949–955
  9. Tanaka K, Weihrauch D, Kehl F, et al. Mechanism of preconditioning by isoflurane in rabbits: a direct role for reactive oxygen species. Anesthesiology. 2002;97:1485–1490
  10. Ludwig LM, Weihrauch D, Kersten JR, et al. Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. Anesthesiology. 2004;100:532–539
  11. Toller WG, Kersten JR, Gross ER, et al. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. Anesthesiology. 2000;92:1400–1407
  12. Toma O, Weber NC, Wolter JI, et al. Desflurane preconditioning induces time-dependent activation of protein kinase C epsilon and extracellular signal-regulated kinase 1 and 2 in the rat heart in vivo. Anesthesiology. 2004;101:1372–1380
  13. Novalija E, Varadarajan SG, Camara AK, et al. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. American Journal of Physiology. Heart and Circulatory Physiology. 2002;283:H44–H52
  14. Chiari PC, Bienengraeber MW, Weihrauch D, et al. Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium. Anesthesiology. 2005;103:74–83
  15. Mullenheim J, Ebel D, Frassdorf J, et al. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology. 2002;96:934–940
  16. Ludwig LM, Tanaka K, Eells JT, et al. Preconditioning by isoflurane is mediated by reactive oxygen species generated from mitochondrial electron transport chain complex III. Anesthesia and Analgesia. 2004;99:1308–1315
  17. Riess ML, Eells JT, Kevin LG, et al. Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology. 2004;100:498–505
  18. Venkatapuram S, Wang C, Krolikowski JG, et al. Inhibition of apoptotic protein p53 lowers the threshold of isoflurane-induced cardioprotection during early reperfusion in rabbits. Anesthesia and Analgesia. 2006;103:1400–1405
  19. Krolikowski JG, Weihrauch D, Bienengraeber M, et al. Role of Erk1/2, p70s6 K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Canadian Journal of Anaesthesia. 2006;53:174–182
  20. Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovascular Research. 2006;70:191–199
  21. Pagel PS, Krolikowski JG, Neff DA, et al. Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesthesia and Analgesia. 2006;102:1348–1354
  22. Krolikowski JG, Bienengraeber M, Weihrauch D, et al. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesthesia and Analgesia. 2005;101:1590–1596
  23. Alcindor D, Krolikowski JG, Pagel PS, et al. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacological preconditioning in vivo. Anesthesiology. 2004;100:547–554
  24. Tanaka K, Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology. 2004;100:525–531
  25. Nakae Y, Kwok WM, Bosnjak ZJ, Jiang MT. Isoflurane activates rat mitochondrial ATP-sensitive K+ channels reconstituted in lipid bilayers. American Journal of Physiology. Heart and Circulatory Physiology. 2003;284:H1865–H1871
  26. Kohro S, Hogan QH, Nakae Y, et al. Anesthetic effects on mitochondrial ATP-sensitive K channel. Anesthesiology. 2001;95:1435–1440
  27. Zaugg M, Lucchinetti E, Spahn DR, et al. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology. 2002;97:4–14
  28. Holmuhamedov E, Jovanovic S, Dzeja P, et al. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. American Journal of Physiology. Heart and Circulatory Physiology. 1998;275:H1567–H1576
  29. Hausenloy D, Yellon D. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research. 2004;61:448–460
  30. Riess ML, Camara AK, Novalija E, et al. Anesthetic preconditioning attenuates mitochondrial Ca2+ overload during ischemia in Guinea pig intact hearts: reversal by 5-hydroxydecanoic acid. Anesthesia and Analgesia. 2002;95:1540–1546
  31. Crompton M. The mitochondrial permeability transition pore and its role in cell death. The Biochemical Journal. 1999;341(Pt 2):233–249
  32. Piriou V, Chiari P, Gateau-Roesch O, et al. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology. 2004;100:581–588
  33. Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. Cardiovascular Research. 2006;70:212–221
  34. Patel HH, Ludwig LM, Fryer RM, et al. Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening. The FASEB Journal. 2002;16:1468–1470
  35. Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. Journal of the American College of Cardiology. 2000;36:2296–2302
  36. Gross ER, Peart JN, Hsu AK, et al. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. American Journal of Physiology. Heart and Circulatory Physiology. 2005;288:H2744–H2749
  37. Ludwig LM, Patel HH, Gross GJ, et al. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology. 2003;98:705–711
  38. Weihrauch D, Krolikowski JG, Bienengraeber M, et al. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesthesia and Analgesia. 2005;101:942–949
  39. Kokita N, Hara A, Abiko Y, et al. Propofol improves functional and metabolic recovery in ischemic reperfused isolated rat hearts. Anesthesia and Analgesia. 1998;86:252–258
  40. Kokita N, Hara A. Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. Anesthesiology. 1996;84:117–127
  41. Sztark F, Ichas F, Ouhabi R, et al. Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential. FEBS Letters. 1995;368:101–104
  42. Cason BA, Gamperl AK, Slocum RE, Hickey RF. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology. 1997;87:1182–1190
  43. Kawano T, Oshita S, Tsutsumi Y, et al. Clinically relevant concentrations of propofol have no effect on adenosine triphosphate-sensitive potassium channels in rat ventricular myocytes. Anesthesiology. 2002;96:1472–1477
  44. Mullenheim J, Frassdorf J, Preckel B, et al. Ketamine, but not S(+)-ketamine, blocks ischemic preconditioning in rabbit hearts in vivo. Anesthesiology. 2001;94:630–636
  45. Mullenheim J, Rulands R, Wietschorke T, et al. Late preconditioning is blocked by racemic ketamine, but not by S(+)-ketamine. Anesthesia and Analgesia. 2001;93:265–270
  46. Ko SH, Lee SK, Han YJ, et al. Blockade of myocardial ATP-sensitive potassium channels by ketamine. Anesthesiology. 1997;87:68–74
  47. Zaugg M, Lucchinetti E, Spahn DR, et al. Differential effects of anesthetics on mitochondrial K(ATP) channel activity and cardiomyocyte protection. Anesthesiology. 2002;97:15–23
  48. Hanouz JL, Zhu L, Persehaye E, et al. Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors. Anesthesiology. 2005;102:1190–1196
  49. Rivo J, Raphael J, Drenger B, et al. Flumazenil mimics whereas midazolam abolishes ischemic preconditioning in a rabbit heart model of ischemia-reperfusion. Anesthesiology. 2006;105:65–71
  50. Riess ML, Camara AK, Rhodes SS, et al. Increasing heart size and age attenuate anesthetic preconditioning in guinea pig isolated hearts. Anesthesia and Analgesia. 2005;101:1572–1576
  51. Lakatta EG, Sollott SJ. Perspectives on mammalian cardiovascular aging: humans to molecules. Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology. 2002;132:699–721
  52. Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. The Journal of Clinical Investigation. 2004;113:1535–1549
  53. Kehl F, Krolikowski JG, Mraovic B, et al. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology. 2002;96:183–188
  54. Tanaka K, Kehl F, Gu W, et al. Isoflurane-induced preconditioning is attenuated by diabetes. American Journal of Physiology. Heart and Circulatory Physiology. 2002;282:H2018–H2023
  55. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56:127–136
  56. Kersten JR, Montgomery MW, Ghassemi T, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. American Journal of Physiology. Heart and Circulatory Physiology. 2001;280:H1744–H1750
  57. Belhomme D, Peynet J, Louzy M, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation. 1999;100:II340–II344
  58. Penta de Peppo A, Polisca P, Tomai F, et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. The Annals of Thoracic Surgery. 1999;68:112–118
  59. Tomai F, De Paulis R, Penta de Peppo A, et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. Giornale Italiano di Cardiologia. 1999;29:1007–1014
  60. Haroun-Bizri S, Khoury SS, Chehab IR, et al. Does isoflurane optimize myocardial protection during cardiopulmonary bypass?. Journal of Cardiothoracic Vascular Anesthesia. 2001;15:418–421
  61. Nader ND, Li CM, Khadra WZ, et al. Anesthetic myocardial protection with sevoflurane. Journal of Cardiothoracic Vascular Anesthesia. 2004;18:269–274
  62. Lee MC, Chen CH, Kuo MC, et al. Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. European Journal of Anaesthesiology. 2006;23:841–847
  63. Conzen PF, Fischer S, Detter C, Peter K. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology. 2003;99:826–833
  64. Pouzet B, Lecharny JB, Dehoux M, et al. Is there a place for preconditioning during cardiac operations in humans?. The Annals of Thoracic Surgery. 2002;73:843–848
  65. Julier K, da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003;98:1315–1327
  66. Lucchinetti E, Hofer C, Bestmann L, et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology. 2007;106:444–457
  67. De Hert SG, ten Broecke PW, Mertens E, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology. 2002;97:42–49
  68. De Hert SG, Cromheecke S, ten Broecke PW, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology. 2003;99:314–323
  69. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology. 2004;101:9–20
  70. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology. 2004;101:299–310
  71. Cromheecke S, Pepermans V, Hendrickx E, et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesthesia and Analgesia. 2006;103:289–296
  72. Garcia C, Julier K, Bestmann L, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. British Journal of Anaesthesia. 2005;94:159–165
  73. Fellahi JL, Gue X, Philippe E, et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. European Journal of Anaesthesiology. 2004;21:688–693
  74. Law-Koune JD, Raynaud C, Liu N, et al. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. Journal of Cardiothoracic Vascular Anesthesia. 2006;20:484–492
  75. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. Journal of Cardiothoracic Vascular Anesthesia. 2006;20:477–483
  76. Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesthesia and Analgesia. 2005;100:610–616
  77. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. British Journal of Anaesthesia. 2006;97:127–136
  78. Kehl F, Krolikowski JG, Mraovic B, et al. Is isoflurane-induced preconditioning dose related?. Anesthesiology. 2002;96:675–680
  79. Murphy GS, Szokol JW, Marymont JH, et al. Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. Journal of Cardiothoracic Vascular Anesthesia. 2006;20:493–502
  80. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(supplementry):789–830
  81. Forlani S, Tomai F, De Paulis R, et al. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. Journal of Cardiovascular Surgery. 2004;45:117–122
  82. Lee TM, Chou TF. Impariment of myocardial protection in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism. 2003;88:531–537
  83. Gu W, Pagel PS, Warltier DC, Kersten JR. Modifying cardiovascular risk in diabetes mellitus. Anesthesiology. 2003;98:774–779
  84. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. American Journal of Cardiology. 2003;92:34J–41J
  85. Yue T, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-y agonist rosiglitazone. Circulation. 2001;104:2588–2594
  86. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. The FASEB Journal. 2002;16:1027–1040
  87. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine. 2007;356:2457–2471
  88. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery. 2003;125:1481–1492
  89. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005;111:249

PII: S1521-6896(07)00078-X

doi: 10.1016/j.bpa.2007.08.003

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 151-165 , March 2008

Article Tools